Hemolytic uremic syndrome presenting after treatment of endodermal sinus tumor

Obstet Gynecol. 2004 Nov;104(5 Pt 2):1184-7. doi: 10.1097/01.AOG.0000142694.74553.4b.

Abstract

Background: Hemolytic uremic syndrome is a rare multisystem disorder that is caused by infections, preeclampsia, autoimmune disorders, or oral contraceptive agents, and rarely in association with different cancers and chemotherapeutic agents.

Case: A 34-year-old woman who presented for evaluation of a pelvic mass received a diagnosis of International Federation of Gynecology and Obstetrics (FIGO) stage 1c endodermal sinus tumor at laparotomy. Three months after receiving 3 courses of bleomycin, etoposide, and cisplatinum, she presented with renal failure, thrombocytopenia, anemia, and severe hypertension. Cancer-associated hemolytic uremic syndrome was diagnosed, and the patient was treated with plasmaphoresis, blood transfusion, and hemodialysis.

Conclusion: Cancer-associated hemolytic uremic syndrome has a high mortality rate; thus, prompt diagnosis is critical to survival.

Publication types

  • Case Reports

MeSH terms

  • Abdominal Pain / diagnosis
  • Abdominal Pain / etiology
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biopsy, Needle
  • Blood Transfusion
  • Chemotherapy, Adjuvant / adverse effects
  • Combined Modality Therapy
  • Endodermal Sinus Tumor / pathology*
  • Endodermal Sinus Tumor / therapy*
  • Female
  • Follow-Up Studies
  • Hemolytic-Uremic Syndrome / chemically induced*
  • Hemolytic-Uremic Syndrome / physiopathology
  • Hemolytic-Uremic Syndrome / therapy
  • Humans
  • Immunohistochemistry
  • Ovarian Neoplasms / pathology*
  • Ovarian Neoplasms / therapy*
  • Ovariectomy / methods
  • Plasmapheresis
  • Renal Dialysis
  • Risk Assessment
  • Treatment Outcome